A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using molnupiravir to treat COVID-19. Published in The Lancet Microbe, the ...
Molnupiravir is the only alternative when first-line therapies (remdesivir and ritonavir-boosted nirmatrelvir) are not ...